Funding
Series D+Debt · Biotech

Full-Life Technologies announces $150m Series D and debt financing

Vivo Capital, SK Biopharmaceuticals, Chengwei Capital and other participants backed the radiotherapeutics company.

Updated Oct 16, 2026By RoundOS Funding desk

Full-Life Technologies announced $150 million in combined Series D and debt financing on May 18. Participants included Vivo Capital, SK Biopharmaceuticals, Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital and TSG Capital.

The clinical-stage company develops targeted cancer radiotherapies with integrated isotope manufacturing.

Funding history

Series D+Debt · This round$150M

Sources

  1. Full-Life Technologiesprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related